The abstract is read at the publisher; the summary is JClub's.
In 45 adults with high-relapse-risk myeloid malignancies or acute leukemia, single-infusion 211At-CD45 radioimmunotherapy established 500 μCi/kg as the maximum tolerated dose.
- Why it matters: Relapse remains the main reason allogeneic HCT fails in aggressive hematologic cancers, and CD45-directed radioimmunotherapy aims to intensify conditioning while limiting off-target toxicity.
- What they did: In a first-in-human two-stage dose-finding study, 211At-labeled anti-CD45 monoclonal antibody was infused before nonmyeloablative fludarabine/2–3 Gy total body irradiation and allografting in 45 adults.
- The result: At 500 μCi/kg, infusion reactions were mild and hematopoietic recovery, donor chimerism, and GVHD rates were not impaired; blasts cleared in 12 of 13, with 1-year relapse-free survival 42% and overall survival 49%.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.